Bladder Cancer Indication for Tecentriq Withdrawn

Genentech, a member of the Roche Group, is voluntarily withdrawing the US accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally advanced or metastatic urothelial carcinoma (bladder cancer). The FDA had granted accelerated approval for Tecentriq in 2018 for patients who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1 or are not eligible for any platinum-containing chemotherapy regardless of PD-L1 status.

Genentech made this decision to withdraw this indictaion following consultation with the FDA after the phase 3 IMvigor130 trial did not meet the co-primary endpoint of overall survival (OS) for Tecentriq plus chemotherapy compared with chemotherapy alone. These data will be presented at an upcoming medical meeting. IMvigor130 was the designated to be the postmarketing trial to convert the accelerated approval to regular approval.

An estimated 81,000 cases of bladder cancer will be diagnosed in the United States in 2022. Urothelial carcinoma, which develops in the cells of the bladder lining, is the most common type of bladder cancer, accounting for about 90% of all cases. In total, 30% of cases are considered advanced based on muscle-invasive or metastatic disease.

“There is a considerable unmet need for effective and tolerable treatments for people living with advanced bladder cancer and so we regret that the IMvigor130 trial did not cross the statistical threshold for overall survival,” Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development, said in a press release.

Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. It is currently approved to treat both small- and non-small cell lung cancer, hepatocellular carcinoma, and melanoma.

Last year, Genentech withdrew the accelerated approval for Tecentriq in combination with chemotherapy (Celgene’s Abraxane, albumin-bound paclitaxel) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1.

This article originally appeared on Formulary Watch.